Thymosin Alpha-1
Thymosin alpha-1 is a thymus-derived peptide with a substantial research literature in immune modulation, including use in several countries as an adjunct therapy.
Also known as: Tα1
Research context
- Isolated originally from the thymus gland.
- Has clinical use in some countries as an immune adjunct.
- Available in 5mg and 10mg.
What thymosin alpha-1 is
Thymosin alpha-1 (Tα1) is a short synthetic peptide — 28 amino acids, acetylated at the N-terminus — that corresponds to a fragment of thymosin fraction 5, the thymus extract first characterised in the 1970s. The acetylation is what separates it from the unmodified fragment: it stabilises the peptide against exopeptidase degradation, which is why the acetylated form is the one that made it into the research literature rather than the parent sequence.
The reason it sits on this shelf at all is its signalling profile. Tα1 is studied as an immunomodulator rather than a direct-acting agent: the published work concerns how it interacts with innate and adaptive immune signalling pathways, not a single receptor target in the way a growth-hormone secretagogue or a GHRH analogue has. That makes it structurally different from almost everything else in the catalogue — it belongs to the immune category because the literature is an immunology literature.
Where it stands in the immune-support category
Most of the peptides sold for immune-related research sit in one of two camps. The first is the antimicrobial class and its derivatives — LL-37 is the clearest example, a cathelicidin fragment studied for direct membrane activity against pathogens. The second is the immunomodulatory signalling class, where the compound is studied less for killing anything directly and more for how it shifts the balance of an immune response. Thymosin alpha-1 is the reference compound of that second camp.
What makes it the reference is documentation depth. Tα1 has a clinical history in several countries as an adjunct therapy, which means its pharmacology, half-life and downstream immune markers are described in controlled human data rather than extrapolated from cell work alone. For a research setting that is the point: you are comparing against a compound with a published human record, not an assay-only curiosity.
Thymosin alpha-1 vs other immune-modulating peptides
| Compound | Class / studied role | Where it differs |
|---|---|---|
| LL-37 | Cathelicidin fragment — direct antimicrobial activity | Studied for membrane-disrupting action on pathogens; a direct-acting peptide rather than a signalling immunomodulator. |
| KPV | Tripeptide — α-MSH fragment, anti-inflammatory signalling | Much shorter sequence acting on a different pathway; studied for anti-inflammatory rather than thymic immunomodulation. |
| Selank | Tuftsin analogue — anxiolytic / immunomodulatory | Also an immunomodulatory peptide, but its literature centres on CNS and anxiolytic endpoints with immune effects secondary. |
| Epitalon | Tetrapeptide — pineal / telomerase research | Studied in a longevity and telomere-maintenance context, not an immune-modulation one. |
The practical takeaway: if the research question is about direct antimicrobial action, LL-37 is the comparator. If it is about thymic immunomodulation with a human data record behind it, thymosin alpha-1 is the one to start from — and the two are studied for genuinely different mechanisms, not as substitutes for each other.
How it is supplied and handled
Thymosin alpha-1 ships as a lyophilised (freeze-dried) powder in a sealed vial — the standard stable form for research peptides. It is available here in 5mg and 10mg vials. Once reconstituted with bacteriostatic water it should be kept refrigerated and handled cold-chain; the general reconstitution guide covers the volumes, the arithmetic and the storage handling that apply to this class of compound.
Every batch is supplied with a certificate of analysis. Our lab and COA policy explains what is tested and what the documentation covers — if you need a batch-specific COA before ordering, ask via the contact page and we will send it.
Ordering, payment and delivery
Pricing is per single vial — no minimum order, no bundle you have to take to get a sensible rate. Card checkout runs on Stripe; bank transfer is available at 10% off and confirms on clearance. UK dispatch is cold-chain, and delivery sets out the timelines and what to expect on arrival.
Common questions
What is thymosin alpha-1 studied for?
It is studied as an immunomodulator — the published literature concerns how it interacts with innate and adaptive immune signalling. It has a clinical history in several countries as an adjunct therapy, which is why its pharmacology is better documented than most peptides in the immune category. Nothing here is medical advice.
How is it different from LL-37 or KPV?
LL-37 is studied for direct antimicrobial membrane activity, and KPV is a short anti-inflammatory signalling fragment. Thymosin alpha-1 is the reference compound of the thymic immunomodulation class, with a human data record behind it. They are studied for different mechanisms rather than being interchangeable.
Is thymosin alpha-1 a research chemical or a medicine?
As sold here, it is a research chemical. It is not a licensed medicine in the UK, it is not for human or veterinary use, and nothing on this page is medical advice or a dosing recommendation.
What strengths do you stock?
5mg and 10mg vials. The 5mg is £19.55 and the 10mg is £32.30 per vial, with a 10% discount on bank transfer.
Does it come with a COA?
Yes — a certificate of analysis accompanies every batch. COA on request before you order if you need the documentation up front.